The Molecular Oncology Almanac: Assertion Details

Assertion: Sensitivity to Avapritinib (in Gastrointestinal Stromal Tumor)
Preclinical

Somatic Variant: KIT Exon 17

Avapritnib inhibited the the profileration of KIT mutant cell lines. Avapritnib also had anti-tumor activity in mice implanted with an imatinib-resistant patient-derived xenograft model of human GIST with an activating KIT exon 11 or 17 variant.

Citations:

Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s007lbl.pdf. Revised June 2021. Accessed September 2nd, 2021.

Assertion: Sensitivity to Avapritinib (in Gastrointestinal Stromal Tumor) Preclinical

Preclinical

Assertion: Sensitivity to Avapritinib (in Gastrointestinal Stromal Tumor)
Preclinical